You searched for
Category:
#Corporate
Purpose First: Chiesi Publishes 2024 Sustainability Report
06/06/2025
Elgan Pharma and Chiesi Group Announce First Participating Infants Dosed in Phase 3 Study of ELGN-2112 for Treatment of Intestinal Malabsorption in Preterm Infants
05/06/2025
Chiesi Group delivers on transformational strategy with FY2024 double-digit growth (13% at CER), strong investment in innovation and continued focus on sustainability
16/04/2025
Chiesi Acquires New Manufacturing Site in Nerviano (Milan) with a Strategic €430 Million Investment To 2030 to Drive Global Growth
26/03/2025
Chiesi Group appoints three new independent Non-Executive Directors to its Board, supporting company evolution and growth
29/01/2025
Great Place To Work and Fortune Name Chiesi Group No. 23 in 2024 World’s Best Workplaces™ List
14/11/2024
Bringing Sustainability and Strategy together to create Shared Value: Insights from Chiesi’s 2023 Sustainability Report
22/07/2024
Chiesi and Gossamer Bio Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in Pulmonary Arterial Hypertension and Other Respiratory Indications
06/05/2024
Chiesi Group's 2023 Revenue Surpasses €3 Billion Mark, Reflecting 10% Growth Year-on-Year (+12% @CER), Underlining Commitment to Innovative, Sustainable Practices
22/04/2024
Chiesi Group announces the passing of Honorary President Dr. Paolo Chiesi (1940-2024)
05/03/2024
Alessandro Chiesi appointed Chair of the Chiesi Group Maria Paola Chiesi becomes the Vice Chair
07/07/2023
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc
12/04/2023
Restore to Impact - The next healthcare landmark for innovation and future-oriented competencies
01/03/2023
Chiesi appoints Giuseppe Accogli as new Group CEO
27/01/2023
Important recognitions for Chiesi Group from the Carbon Disclosure Project (CDP) and Cerved Rating Agency
17/01/2023